 |
PDBsum entry 2i0v
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.1
- receptor protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
282:4094-4101
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors.
|
|
C.Schubert,
C.Schalk-Hihi,
G.T.Struble,
H.C.Ma,
I.P.Petrounia,
B.Brandt,
I.C.Deckman,
R.J.Patch,
M.R.Player,
J.C.Spurlino,
B.A.Springer.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The cFMS proto-oncogene encodes for the colony-stimulating factor-1 receptor, a
receptor-tyrosine kinase responsible for the differentiation and maturation of
certain macrophages. Upon binding its ligand colony-stimulating factor-1 cFMS
autophosphorylates, dimerizes, and induces phosphorylation of downstream
targets. We report the novel crystal structure of unphosphorylated cFMS in
complex with two members of different classes of drug-like protein kinase
inhibitors. cFMS exhibits a typical bi-lobal kinase fold, and its activation
loop and DFG motif are found to be in the canonical inactive conformation. Both
ATP competitive inhibitors are bound in the active site and demonstrate a
binding mode similar to that of STI-571 bound to cABL. The DFG motif is
prevented from switching into the catalytically competent conformation through
interactions with the inhibitors. Activation of cFMS is also inhibited by the
juxtamembrane domain, which interacts with residues of the active site and
prevents formation of the activated kinase. Together the structures of cFMS
provide further insight into the autoinhibition of receptor-tyrosine kinases via
their respective juxtamembrane domains; additionally the binding mode of two
novel classes of kinase inhibitors will guide the design of novel molecules
targeting macrophage-related diseases.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
FIGURE 1. A, overview of the cFMS structure (TIE2-KID) with
bound inhibitor 1. Structural elements are color-coded: blue,
(N)ucleotide binding loop (P-loop); red, activation loop; green,
catalytic loop; salmon, hinge region; cyan, KID; yellow, JM
domain. B, structures of the inhibitors used in this study, 1
arylamide series inhibitor, 2 quinolone series inhibitor.
|
 |
Figure 3.
FIGURE 3. Role of the JM domain in stabilizing the inactive
form of cFMS. cFMS is shown in a white surface representation,
the activation loop (red) and the JM domain (yellow) were
excluded from the surface calculation and are represented as red
and yellow schemes, respectively. Trp^550 is also represented as
a surface. The activation loop of activated cKIT (PDB-ID 1PKG),
superimposed onto cFMS, is shown in green. In its autoinhibited
state, the JM domain of cFMS inserts itself into the active site
and prevents the activation loop from switching into an active
conformation.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2007,
282,
4094-4101)
copyright 2007.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
K.Verstraete,
and
S.N.Savvides
(2012).
Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.
|
| |
Nat Rev Cancer,
12,
753-766.
|
 |
|
|
|
|
 |
L.M.Wodicka,
P.Ciceri,
M.I.Davis,
J.P.Hunt,
M.Floyd,
S.Salerno,
X.H.Hua,
J.M.Ford,
R.C.Armstrong,
P.P.Zarrinkar,
and
D.K.Treiber
(2010).
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
|
| |
Chem Biol,
17,
1241-1249.
|
 |
|
|
|
|
 |
M.Rabiller,
M.Getlik,
S.Klüter,
A.Richters,
S.Tückmantel,
J.R.Simard,
and
D.Rauh
(2010).
Proteus in the world of proteins: conformational changes in protein kinases.
|
| |
Arch Pharm (Weinheim),
343,
193-206.
|
 |
|
|
|
|
 |
S.Bhattacharyya,
W.Ishida,
M.Wu,
M.Wilkes,
Y.Mori,
M.Hinchcliff,
E.Leof,
and
J.Varga
(2009).
A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.
|
| |
Oncogene,
28,
1285-1297.
|
 |
|
|
|
|
 |
N.Brownlow,
A.E.Russell,
H.Saravanapavan,
M.Wiesmann,
J.M.Murray,
P.W.Manley,
and
N.J.Dibb
(2008).
Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis.
|
| |
Leukemia,
22,
649-652.
|
 |
|
|
|
|
 |
M.Ikuta,
M.Kornienko,
N.Byrne,
J.C.Reid,
S.Mizuarai,
H.Kotani,
and
S.K.Munshi
(2007).
Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors.
|
| |
Protein Sci,
16,
2626-2635.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |